The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?
examines the pricing trajectories in the United States of disease-modifying therapies (DMT) for MS over the last 20 years and assess the influences on rising prices.
Estimated annual cost of MS DMT 1993-2016 (.pdf)
Daniel Hartung, PharmD, MPH and Dennis Bourdette, MD of Oregon Health & Science University track the rising cost of 14 disease-modifying therapies from the introduction of the first DMT in 1993 to 2016.
Medicare Beneficiaries Face Growing Out-of-Pocket Burden for Specialty Drugs While in Catastrophic Coverage Phase
analyzed trends in total and out-of-pocket spending among Medicare beneficiaries who take at least one high-cost specialty drug from the top eight specialty drug classes in terms of spending, using 2008-2012 pharmacy claims data from a 20 percent sample of Medicare beneficiaries.
Medicare Part D in 2016 and Trends over Time
The Henry J. Kaiser Family Foundation presents findings on the 2016 Medicare Part D marketplace and trends since 2006. Since 2006, Medicare beneficiaries have had access to prescription drug coverage offered by private plans, either stand-alone prescription drug plans (PDPs) or Medicare Advantage drug plans (MA-PD plans).
GSK CEO Andrew Witty says drugmakers need to be empathetic and not try to defend price hikes
Andrew Witty, the chief executive of British pharmaceutical giant GSK, told CNBC, "In all circumstance, we need to be realistic and empathetic, we need to demonstrate better that we understand people are concerned about [drug pricing]," on the sidelines of the Singapore Summit 2016.
Allergan: Our Social Contract With Patients
Allergan CEO Brent Saunders explains their social contract with patients. By doing so, Brent conveys to his Allergan colleagues that they must keep this social contract in mind as they make business decisions that ultimately improve wellbeing, and as a result, address the hopes others place in them.
The Complex Math Behind Spiraling Prescription Drug Pricing
Katie Thomas of The New York Times
uncovers the controversy over drug pricing, how much drugs cost, and what that means for patients.
Health insurance affects the use of disease-modifying therapy in MS
evaluates the association between health insurance coverage and DMT use for MS. Insurance coverage affects DMT use for persons with MS, and use of free/discounted drug programs is substantial and makes economic analysis that ignores these supplements potentially inaccurate.